Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The European Gazette.
Press releases published on April 16, 2025
Arowana launches S$120 million B Corp holding company out of Singapore, appoints B Lab Global co-founder Andrew Kassoy and Thomas Ng to Advisory Board
GlobeNewswire
·
April 16, 2025
Arowana’s B Corp holding company will provide a succession and ownership transition pathway for B Corp founders seeking to exit but retain ethos of their businesses Investment focus will initially be on ASEAN region but in time look to expand to other …
Conditional Issuance of Shares
GlobeNewswire
·
April 16, 2025
INSIDE INFORMATION REGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), today announced a conditional issuance …
Émission Conditionnelle d’Actions
GlobeNewswire
·
April 16, 2025
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Émission Conditionnelle d’Actions Mont-Saint-Guibert, Belgique – le 16 avril 2025, 8:00h CET / 2:00h ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” ou la “Société”), a annoncé aujourd’hui une …
VALLOUREC REÇOIT LA NOTATION « INVESTMENT GRADE » ET PUBLIE LES REVISIONS A LA HAUSSE DES TROIS PRINCIPALES AGENCES DE NOTATION
GlobeNewswire
·
April 16, 2025
Communiqué de presse VALLOUREC REÇOIT LA NOTATION « INVESTMENT GRADE » ET PUBLIE LES REVISIONS A LA HAUSSE DES TROIS PRINCIPALES AGENCES DE NOTATION Meudon (France), le 16 avril 2025 – Vallourec, un leader mondial des solutions tubulaires premium sans …
Vallourec Receives an Investment Grade Rating and Reports Positive Rating Actions by All Three Agencies
GlobeNewswire
·
April 16, 2025
VALLOUREC RECEIVES AN INVESTMENT GRADE RATING AND REPORTS POSITIVE RATING ACTIONS BY ALL THREE AGENCIES Meudon (France), April 16, 2025 – Vallourec, a world leader in premium seamless tubular solutions, announces several positive developments in its credit …
Basilea berichtet über Präsentation neuer Daten zu Fosmanogepix, Isavuconazol (Cresemba®) und Ceftobiprol (Zevtera®) auf dem Fachkongress ESCMID Global 2025
GlobeNewswire
·
April 16, 2025
Allschwil, 16. April 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab …
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
GlobeNewswire
·
April 16, 2025
Allschwil, Switzerland, April 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today scientific …
ZA FUNDINGS LTD erhöht die Sicherheit beim Cloud-Mining mit Cold Wallet Storage und Schutzmaßnahmen auf Unternehmensebene
GlobeNewswire
·
April 16, 2025
Bild von ZA FUNDINGS LTD BERLIN, April 16, 2025 (GLOBE NEWSWIRE) -- ZA FUNDINGS LTD, ein führender Anbieter von Cloud-Mining-Diensten, hat ein umfassendes Upgrade seiner Sicherheitsinfrastruktur angekündigt, um die Gelder der Nutzer besser zu schützen und …
Technip Energies awarded a FEED contract for Jet Zero’s Sustainable Aviation Fuel project in Australia
GlobeNewswire
·
April 16, 2025
Technip Energies (PARIS:TE) has been awarded a Front-End Engineering Design (FEED) contract by Jet Zero Australia Pty Ltd (Jet Zero) for Project Ulysses, a bioethanol to sustainable aviation fuel (SAF) project located in Townsville, Australia. The FEED …
Technip Energies remporte un contrat d'ingénierie d'avant-projet détaillé pour le projet de carburant d'aviation durable de Jet Zero en Australie
GlobeNewswire
·
April 16, 2025
Technip Energies (PARIS : TE) a remporté un contrat auprès de Jet Zero Australia Pty Ltd (Jet Zero) pour réaliser l'ingénierie d'avant-projet détaillé (FEED) du projet Ulysse, visant à convertir du bioéthanol en carburant d'aviation durable (SAF) à …
Santhera informiert über den kommerziellen Rollout von AGAMREE®
GlobeNewswire
·
April 16, 2025
Pratteln, Schweiz, 16. April 2025 - Santhera Pharmaceuticals (SIX: SANN) gibt den neuesten Fortschritt beim kommerziellen Rollout von AGAMREE® zur Behandlung von Duchenne-Muskeldystrophie (DMD) bekannt. Für AGAMREE zur Behandlung von Duchenne- …
Santhera shares updates on commercial rollout of AGAMREE®
GlobeNewswire
·
April 16, 2025
Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD). Funding from National Health Service (NHS) England is …
HERE Technologies Showcases Software-Defined Vehicle Solutions for Chinese Automakers at Auto Shanghai 2025
GlobeNewswire
·
April 16, 2025
HERE to showcase next-generation, AI-powered mapping and location solutions built for the connected, electric, automated and intelligent vehicle era Working alongside 30 leading Chinese automakers globally, HERE is the trusted provider for high-quality …
ASML reports €7.7 billion total net sales and €2.4 billion net income in Q1 2025
GlobeNewswire
·
April 16, 2025
ASML reports €7.7 billion total net sales and €2.4 billion net income in Q1 2025 2025 total net sales expected to be between €30 billion and €35 billion VELDHOVEN, the Netherlands, April 16, 2025 – Today, ASML Holding NV (ASML) has published its 2025 first …
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
GlobeNewswire
·
April 16, 2025
Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay. Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma. Confirmation of full …
Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l’exercice 2025
GlobeNewswire
·
April 16, 2025
Croissance des ventes de 11,6% à taux de change constant1, ou 11,7% en données publiées, tirée par toutes les aires thérapeutiques, incluant une contribution croissante d'Iqirvo et de Bylvay. Soumission réglementaire à l'EMA2 de tovorafenib pour le gliome …